Metabolic Test With Fluorine-18-Fluorodeoxyglucose in Staging and Detection of Residual Tumor or Recurrence in Hodgkin Lymphoma

Pracchia, Luís Fernando; Chaves, Anna Alice Rolim; Cerci, Juliano Júlio; Soares, José; Meneghetti, José Cláudio; Buccheri, Valéria

doi:10.1590/s1807-59322007000200005

Cited by 6 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic testing with fluorine-18-fluorodeoxyglucose has also been described for detecting residual tumor or recurrence 14. The sensitivity of PET for detecting organ involvement was also higher than that determined for CT (96.2% vs. 40.0%, respectively), particularly for the evaluation of splenic involvement.…”

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography With 2-[18F]-Fluoro-2-Deoxy-D-Glucose For Initial Staging Of Hodgkin Lymphoma: A Single Center Experience In Brazil

Cerci

Pracchia

Soares

et al. 2009

Clinics

Self Cite

View full text Add to dashboard Cite

PURPOSE:The aim of the present study was to investigate the effectiveness of FDG-PET in the initial staging of HL patients in a Brazilian population. METHODS: Eighty-two patients with newly diagnosed HL were prospectively included in the study. All patients were staged with both conventional clinical staging (CCS) methods, including computed tomography (CT) and whole-body FDG-PET methods. A standard of reference for the nodal regions and the extranodal organs was determined using all available information, including the CCS methods, FDG-PET, the diagnostic histology and the follow-up examinations. The results of the CCS were then compared to the FDG-PET results. RESULTS:The sensitivity of FDG-PET was higher for nodal staging than that of CT (87.8% vs. 61.6%, respectively). FDG-PET was also more sensitive than CT in regard to evaluating the extranodal organs for lymphomatous involvement (96.2% vs. 40.0%, respectively). FDG-PET detected all 16 patients who were characterized by a positive bone marrow biopsy and identified an additional 4 patients with bone marrow disease. The incorporation of FDG-PET coupled with CCS in the staging procedure upstaged 20% (17/82) of the patients and downstaged 11% (9/82) of the patients. As a result of these changes in staging, 15% (13/82) of the patients would have received a different therapeutic regimen. CONCLUSIONS: The FDG-PET method is superior to CT for the detection of nodal and extra-nodal HL. The observation that the FDG-PET method upstaged the disease was the most common result (20% of patients) brought about by the addition of PET to the staging algorithm, even in a population of patients with a high incidence of advanced disease. However, changes in stages based on FDG-PET results should be confirmed by biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%